HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
MRK
Merck & Co., Inc.
MRK's fundamentals are mixed, but it looks expensive: trading at 151x earnings, about seven times its usual 21x. Its downside scenario is about eight times its upside.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
MRK Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Strong | |
| Weak |
MRK's cash flow is currently strong, and its revenue and profitability are stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
MRK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 15x | $14.38 | -90% |
| Forward | 17x | $147 | — |
| Fair | 21x | $20.03 | -86% |
| Expensive | 58x | $55.80 | -62% |
| Current | 151x | $147 | — |
Historical ranges are pointers, not guarantees.
MRK's PE is in its expensive range at 151x. If earnings grow as analysts expect, today's price would be 17x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
MRK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect MRK's earnings to grow and its profitability to improve, with its revenue holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
MRK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.42 | +768% |
| Q3 2026 | $0.97 | -87% |
| Q2 2026 | $1.25 | -81% |
| Q1 2026 | $3.55 | -48% |
| Q4 2025 | $7.28 | +8% |
| Q3 2025 | $7.58 | +59% |
| Q2 2025 | $6.50 | +21% |
| Q1 2025 | $6.88 | +664% |
| Q4 2024 | $6.74 | +4714% |
MRK has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over MRK on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
MRK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.1B | +4.7% |
| Q2 2026 | $16.6B | +5.1% |
| Q1 2026 | $16.3B | +4.9% |
| Q4 2025 | $16.4B | +5% |
| Q3 2025 | $17.3B | +3.7% |
| Q2 2025 | $15.8B | -1.9% |
| Q1 2025 | $15.5B | -1.6% |
| Q4 2024 | $15.6B | +6.8% |
MRK's revenue has grown year over year for five quarters in a row: $18.1B last quarter, up 4.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 31% | -8.3 points |
| Q2 2026 | -4.1% | -36 points |
| Q1 2026 | -22% | -60 points |
| Q4 2025 | 21% | -5.8 points |
| Q3 2025 | 39% | +15 points |
| Q2 2025 | 32% | -5.7 points |
| Q1 2025 | 38% | +2.1 points |
| Q4 2024 | 27% | +41 points |
MRK has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over MRK on cash flow, with more consistent year-over-year improvement.
MRK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $5.5B | -19% |
| Q2 2026 | $4.5B | +77% |
| Q1 2026 | $2.9B | +150% |
| Q4 2025 | $1.8B | -27% |
| Q3 2025 | $6.8B | -20% |
| Q2 2025 | $2.5B | -48% |
| Q1 2025 | $1.2B | -47% |
| Q4 2024 | $2.5B | +$3.3B |
MRK generated $14.7B in free cash flow over the past year, up 13% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over MRK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
MRK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +8M shares |
| 1 year | -0.8% | -20M shares |
| 3 years | -2.7% | -68M shares |
| 5 years | -2.3% | -58M shares |
| Available history | -8.4% | -226M shares |
MRK has 2.5B diluted shares, down 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $653M |
| Q2 2026 | $757M |
| Q1 2026 | $874M |
| Q4 2025 | $1.3B |
| Q3 2025 | $1.3B |
| Q2 2025 | $1.3B |
| Q1 2025 | $1.2B |
| Q4 2024 | $489M |
MRK spent $3.5B buying back its own shares over the past year, down 18% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
MRK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.4x | High |
| Q2 2026 | 5.1x | High |
| Q1 2026 | 3.0x | Moderate |
| Q4 2025 | 1.4x | Healthy |
| Q3 2025 | 1.0x | Very low |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.2x | Healthy |
| Q4 2024 | 1.1x | Healthy |
MRK's net debt is about 5.4 years of its operating earnings (EBITDA), up from a year a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
MRK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.5 | Neutral |
| Stochastic | 69.3 | Neutral |
MRK's weekly RSI is 61 (neutral) and its Stochastic is 69 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
MRK PE vs Healthcare Sector
| Metric | MRK | Sector median | Relative |
|---|---|---|---|
| PE | 151x | 26x | 486% above |
| PE % | 98 | 29 | 69 pts above |
MRK is trading at 151x earnings, a 486% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
MRK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $146.6 | 0.2% above |
| 20 week MA | $141.1 | 4.2% above |
| 50 week MA | $125.2 | 17% above |
| 100 week MA | $105.9 | 39% above |
| 200 week MA | $109.8 | 34% above |
MRK has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
MRK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $87.3 | $76.4 | -12% |
| 2021 | $76.4 | $75.7 | -0.9% |
| 2022 | $75.7 | $111.9 | +48% |
| 2023 | $111.9 | $109.0 | -2.5% |
| 2024 | $109.0 | $99.7 | -8.5% |
| 2025 | $99.7 | $106.8 | +7.1% |
| 2026 YTD | $106.8 | $147.0 | +38% |
MRK has the edge over HIMS on returns for 2026, with the stronger performance.